


Our History

Vision Clinical Research (VCR) originally functioned as a subsidiary of Vision Biotechnology Consulting (VBC). VBC was founded in 1996 by Mark J. Sarno, eJD. VBC has guided biotech and pharmaceutical companies to more than 100+ successful regulatory approvals, clearances, or CLIA waivers in the United States and multiple CE Mark certifications or marketing authorization application (MAA) approvals in foreign countries. In synergy with VBC, Dr. Sarno brought together the talents of VBC and other long-term collaborators and scientific colleagues to build the VCR subsidiary as a contract research organization (CRO) service provider to existing and new clients in the *in vitro* diagnostic (IVD), medical device, and pharmaceutical industries. Eventually, VCR reorganized as an independent limited liability company (LLC) with the same staff retained under the independent entity.

The VCR staff has designed, managed, monitored, analyzed, and reported medical device and IVD studies up to several thousand patients and Phase I-IV drug studies in multiple clinical areas. As such, VCR presents clients with a long pedigree of success in IVD, medical device, and pharmaceutical development. Biographies of the VCR LLC principals and staff are presented at right.


Our Team

- **Mark J. Sarno, eJD – Chief Executive Officer**




Dr. Sarno has over 40 years' experience in research, development, clinical/regulatory, biostatistics, and project management within the pharmaceutical, *in vitro* diagnostics, and medical device fields. He has developed products covering such diverse clinical areas as oncology, cardiovascular disease, diabetes, infectious disease, metabolic bone disease, rheumatology, fetal anomalies, newborn screening, thrombophilia, asthma, and gastroenterology. He is a patented inventor, member of the United States Patent Bar and an associate member of the California Lawyers Association. He founded Vision Biotechnology Consulting, which has for 27 years assisted companies in design, development, clinical research, and regulatory affairs resulting in 51 FDA clearances and approvals. He was also previously Director of Product Development at NovaDx Inc., which developed the first specific *in vitro* diagnostic test for rheumatoid arthritis and osteoarthritis. As a biostatistician, Dr. Sarno has analyzed some of the seminal epidemiological studies in cardiovascular disease including the Atherosclerosis Risk in Communities (ARIC) study as well as international oncology studies such as REDUCE. He has authored book chapters including a chapter in the Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, and published in many prestigious journals such as Journal of Urology, Urology, Diabetes Care, Food and Drug Law, Journal of the American College of Cardiology, Journal of Clinical Pharmacology, Clinical Chemistry, Clinical Biochemistry, Prostate Cancer and Prostatic Disease, Gynecologic Oncology, Fertility and Sterility, and Cancer Research. In his occasional spare time, Dr. Sarno enjoys running, flying airplanes, riding motorcycles, rescuing German Shepherds, and playing drums, keyboards, and bass guitar.

- **Michael Lichtman, BS – Chief Operating Officer**




Mr. Lichtman has over 27 years of both basic research and clinical trials experience and has worked extensively in all four pharmaceutical phases, and *in vitro* diagnostic trials. He has assisted past companies in regulatory affairs, clinical monitoring and project management of trials resulting in 18 FDA approvals or clearances. He was also previously on the research team at NovaDx Inc. which successfully developed *in vitro* diagnostic tests for rheumatoid and osteoarthritis. At Vision Clinical Research, Mr. Lichtman specializes in providing study operations planning and execution, clinical site identification and activation, and site management of trials. In addition to project and site management, he is actively involved in protocol/CRF design; informed consent creation; CRA training; development of study specific documents and tracking tools; investigator selection; and study site contract negotiations. Mr. Lichtman holds a BS Degree in Biology from California State University, San Marcos. In his free time, this Marine Corp Veteran enjoys flying airplanes, running, and surfing. He serves as Treasurer and Board of Director for a local 501(c)(3) non-profit, and is a volunteer wildlife rescuer.

- **Laura Sarno, BS – Chief Information Officer**




Ms. Sarno has 43 years combined experience in academia and industry. Her academic research scientist experience was at Stanford University Medical School in the departments of pediatric infectious diseases and pediatric endocrinology. Her extensive industry experience includes leadership responsibilities as a research scientist, product development scientist, clinical scientist, regulatory affairs professional, project manager/director, and data management director. She has worked extensively in multiple clinical fields including breast and prostate cancer, general urology, dermatology/dermatologic surgery, Alzheimer's disease, metabolic bone disease, maternal fetal medicine, and asthma. Ms. Sarno holds a BS Degree in Biological Sciences from the University of California, Irvine. She currently directs the data management function within Vision Clinical Research for all ongoing studies. Her other pursuits include 7 years as a managing member in a German Shepherd Dog Rescue volunteer organization. She obtained IRS 501(c)(3) nonprofit certification for the Rescue and served 3 years as Secretary/Treasurer for the nonprofit.

- **Diane L. Crombie Hogan, BA – Associate Member**



Ms. Hogan holds a B.A. in Animal Physiology from the University of California, San Diego and has over 30 years of experience in research and drug development, including more than 14 years monitoring clinical trials. She serves as liaison between the sponsor and the investigator, traveling to investigational sites to conduct site evaluation, initiation, periodic monitoring, and termination visits to verify that the rights and well-being of human subjects are protected; that the reported trial data are complete, accurate, and verifiable per source documents; and that the trial is conducted in compliance with the currently approved protocol, Good Clinical Practice, and standard operating procedures. In addition, she also mentors junior clinical research associates (CRAs). Areas of experience include men's and women's health, Preeclampsia, oncology (bladder, prostate, head and neck, gynecological), gastroenterology, diabetes, obesity, insulin sensitivity, and hypertension. She has published over 45 papers, book chapters and abstracts in peer-reviewed medical journals.

- **Christine Kavanagh, BHS, MT (ASCP) – Associate Member**



Ms. Kavanagh has over 33 years in the clinical laboratory and research fields. She started her career as a Clinical Laboratory Scientist at Humana Hospital in Lexington, KY. While there she also served on the Safety and Chemical Hygiene team. She entered the clinical research arena in the mid-1990s as a Clinical Research Associate. She has broad clinical trials experience encompassing numerous therapeutic areas including complex protocols in neurology, oncology, pulmonary, and ophthalmology. Ms. Kavanagh has worked on all phases of clinical trials from first-in-human to post-marketing, and with all manner of investigational product, i.e. drugs, biologics, devices, and diagnostics. Ms. Kavanagh has participated in global studies, adult and pediatric populations, inpatient/outpatient settings, and studies for orphan diseases. Companies she has worked with include Genentech, Teva Neurosciences, Gilead, AstraZeneca, and Progenity, as well as the National Institutes of Health. Her primary areas of focus have been Stroke, Parkinson's Disease, Multiple Sclerosis, Alzheimer's Disease, Multiple System Atrophy, Macular Degeneration, Cystic Fibrosis, Preeclampsia, Hypertension, *in vitro* diagnostics, Diabetes, Infectious Diseases, Arthritis, hematologic malignancies, and stem cell transplant.

Ms. Kavanagh has been associated with several FDA approvals including: Lucentis (ranibizumab) approved to treat age-related Macular Degeneration, Azilect (rasagiline) for Parkinson's Disease, and Enbrel (etanercept) approved for treatment of Psoriatic Arthritis.

Ms. Kavanagh holds a Bachelor of Health Sciences degree from the University of Kentucky and is board certified by the American Society of Clinical Pathologists. She currently functions as a Project Manager at Vision Clinical Research.

- **Howard Birndorf, MS ScD – Business Development**

Dr. Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego. California. Along with former University of California professor and current venture capitalist Tom Roylston, Birndorf founded San Diego's first biotech in 1978, the monoclonal antibody company, Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Birndorf went on to found a number of other successful companies including Gen-Probe, IDEC, IDE, and Biogen-Idec, and Ligand Pharmaceuticals. Birndorf was also involved in the formation of Genentech (Genentech) and was a founding Director of Neurocrine Biosciences. He was the founder and co-chair of the Coalition for 21st Century Medicine and was founder, Chairman and CEO of Nanogen, Inc. Birndorf received his B.A. in Biology from Oakland University, an M.S. in Biochemistry from Wayne State University, and has received honorary Doctor of Science degrees from Oakland University and Wayne State University.

- **Philip E. Silkoff, MB – Medical Monitor and Consulting Pulmonologist**

Philip E. Silkoff is an adult pulmonary physician who transitioned from academia to industry in 2004. His academic research focused on the measurement of exhaled nitric oxide (NO) as it pertains to respiratory medicine. Exhaled NO is a marker of airway inflammation, and Phil developed patented techniques for NO measurement in man, chaired several societal workshops and published extensively in the field of biomarkers in asthma and COPD. His pharmaceutical career has focused on late phase projects in asthma and COPD, culminating in a successful sNDA filing in 2008 for a COPD therapeutic at AstraZeneca. He subsequently worked in early pulmonary drug development in asthma, COPD, ILD, and sarcoidosis at Janssen. In 2016, he became chief medical officer at Third Pole Therapeutics in Boston which is developing inhaled NO for the treatment of pulmonary hypertension. Phil was involved in a clinical trial run by VCR in 2016 and in 2020 joined VCR as a pulmonary consultant for VCR's projects.

- **Dennis L. Broyles, BA, MSHS, RAC, CCRP, CCR – Project Manager**

Mr. Broyles is an experienced assay developer and clinical scientist with over 35 years in the IVD industry. His prior work at Hybritech, Inc. and Beckman Coulter, Inc. includes a number of PMA, de novo 510(k), and 510(k)s products in the areas of prostate cancer, women's reproductive health, infectious disease, hematology, immunology, bone remodeling, and molecular diagnostics. He is well versed in GCP and all aspects of clinical operations, including strategic planning, protocol development, and interacting with FDA. He is certified through the Regulatory Affairs Professionals Society (RAPS) and is a member of the Society of Clinical Research Associates (SCRA). Dennis earned his MSHS degree in Clinical Research Administration from the Johns Hopkins University School of Medicine and has received an Honorary Doctor of Science degree from the University of Maryland.

- **T. Che Jarrell, BSPH, MPA, RAC – Regulatory/QA Specialist**

She has worked in the biotech sector since the mid-90s. She began her career as a SAS statistical programmer and clinical data analyst for the private sector after graduating from the University of North Carolina at Chapel Hill's biostatistics under graduate program. She later transitioned her industry understanding via entering the University of California San Diego's international affairs graduate degree program. Upon graduation and subsequent obtaining of the Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS) in the mid-2000's, Che has transitioned from clinical trial analytics to quality assurance and regulatory affairs. After working for the global pharmaceuticals health care industry in regulatory affairs and quality assurance, Che has been a frequent speaker at the Society of Clinical Research Associates (SCRA), the Johns Hopkins Health System, and other related biomedical product organizations.

- **Jewell Wright, BS, ASCP – Senior Clinical Research Associate**

Ms. Wright has over 40 years in the clinical laboratory and research fields. She began her career as a Clinical Research Associate at Hendrick Hospital in Abilene, Texas. She later moved on to become the Lab Director at Hurst-Euless-Bedford Hospital and later moved on to become the Lab Director at Hurst-Euless-Bedford Hospital in the Dallas-Ft. Worth area.

- **Christine Kavanagh, BHS, MT (ASCP) – Associate Member**

Ms. Kavanagh has over 33 years in the clinical laboratory and research fields. She started her career as a Clinical Laboratory Scientist at Humana Hospital in Lexington, KY. While there she also served on the Safety and Chemical Hygiene team. She entered the clinical research arena in the mid-1990s as a Clinical Research Associate. She has broad clinical trials experience encompassing numerous therapeutic areas including complex protocols in neurology, oncology, pulmonary, and ophthalmology. Ms. Kavanagh has worked on all phases of clinical trials from first-in-human to post-marketing, and with all manner of investigational product, i.e. drugs, biologics, devices, and diagnostics. Ms. Kavanagh has participated in global studies, adult and pediatric populations, inpatient/outpatient settings, and studies for orphan diseases. Companies she has worked with include Genentech, Teva Neurosciences, Gilead, AstraZeneca, and Progenity, as well as the National Institutes of Health. Her primary areas of focus have been Stroke, Parkinson's Disease, Multiple Sclerosis, Alzheimer's Disease, Multiple System Atrophy, Macular Degeneration, Cystic Fibrosis, Preeclampsia, Hypertension, *in vitro* diagnostics, Diabetes, Infectious Diseases, Arthritis, hematologic malignancies, and stem cell transplant.

- **Howard Birndorf, MS ScD – Business Development**

Dr. Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego. California. Along with former University of California professor and current venture capitalist Tom Roylston, Birndorf founded San Diego's first biotech in 1978, the monoclonal antibody company, Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Birndorf went on to found a number of other successful companies including Gen-Probe, IDEC, IDE, and Biogen-Idec, and Ligand Pharmaceuticals. Birndorf was also involved in the formation of Genentech (Genentech) and was a founding Director of Neurocrine Biosciences. He was the founder and co-chair of the Coalition for 21st Century Medicine and was founder, Chairman and CEO of Nanogen, Inc. Birndorf received his B.A. in Biology from Oakland University, an M.S. in Biochemistry from Wayne State University, and has received honorary Doctor of Science degrees from Oakland University and Wayne State University.

- **Philip E. Silkoff, MB – Medical Monitor and Consulting Pulmonologist**

Philip E. Silkoff is an adult pulmonary physician who transitioned from academia to industry in 2004. His academic research focused on the measurement of exhaled nitric oxide (NO) as it pertains to respiratory medicine. Exhaled NO is a marker of airway inflammation, and Phil developed patented techniques for NO measurement in man, chaired several societal workshops and published extensively in the field of biomarkers in asthma and COPD. His pharmaceutical career has focused on late phase projects in asthma and COPD, culminating in a successful sNDA filing in 2008 for a COPD therapeutic at AstraZeneca. He subsequently worked in early pulmonary drug development in asthma, COPD, ILD, and sarcoidosis at Janssen. In 2016, he became chief medical officer at Third Pole Therapeutics in Boston which is developing inhaled NO for the treatment of pulmonary hypertension. Phil was involved in a clinical trial run by VCR in 2016 and in 2020 joined VCR as a pulmonary consultant for VCR's projects.

- **Dennis L. Broyles, BA, MSHS, RAC, CCR, CCRP** – Project Manager

Mr. Broyles is an experienced assay developer and clinical scientist with over 35 years in the IVD industry. His prior work at Hybritech, Inc. and Beckman Coulter, Inc. includes a number of PMA, de novo 510(k), and 510(k)s products in the areas of prostate cancer, women's reproductive health, infectious disease, hematology, immunology, bone remodeling, and molecular diagnostics. He is well versed in GCP and all aspects of clinical operations, including strategic planning, protocol development, and interacting with FDA. He is certified through the Regulatory Affairs Professionals Society (RAPS) and is a member of the Society of Clinical Research Associates (SCRA). Dennis earned his MSHS degree in Clinical Research Administration from the Johns Hopkins University School of Medicine and has received an Honorary Doctor of Science degree from the University of Maryland.

- **T. Che Jarrell, BSPH, MPA, RAC – Regulatory/QA Specialist**

She has worked in the biotech sector since the mid-90s. She began her career as a SAS statistical programmer and clinical data analyst for the private sector after graduating from the University of North Carolina at Chapel Hill's biostatistics under graduate program. She later transitioned her industry understanding via entering the University of California San Diego's international affairs graduate degree program. Upon graduation and subsequent obtaining of the Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS) in the mid-2000's, Che has transitioned from clinical trial analytics to quality assurance and regulatory affairs. After working for the global pharmaceuticals health care industry in regulatory affairs and quality assurance, Che has been a frequent speaker at the Society of Clinical Research Associates (SCRA), the Johns Hopkins Health System, and other related biomedical product organizations.

- **Jewell Wright, BS, ASCP – Senior Clinical Research Associate**

Ms. Wright has over 40 years in the clinical laboratory and research fields. She began her career as a Clinical Research Associate at Hendrick Hospital in Abilene, Texas. She later moved on to become the Lab Director at Hurst-Euless-Bedford Hospital and later moved on to become the Lab Director at Hurst-Euless-Bedford Hospital in the Dallas-Ft. Worth area.

- **Christine Kavanagh, BHS, MT (ASCP) – Associate Member**

Ms. Kavanagh has over 33 years in the clinical laboratory and research fields. She started her career as a Clinical Laboratory Scientist at Humana Hospital in Lexington, KY. While there she also served on the Safety and Chemical Hygiene team. She entered the clinical research arena in the mid-1990s as a Clinical Research Associate. She has broad clinical trials experience encompassing numerous therapeutic areas including complex protocols in neurology, oncology, pulmonary, and ophthalmology. Ms. Kavanagh has worked on all phases of clinical trials from first-in-human to post-marketing, and with all manner of investigational product, i.e. drugs, biologics, devices, and diagnostics. Ms. Kavanagh has participated in global studies, adult and pediatric populations, inpatient/outpatient settings, and studies for orphan diseases. Companies she has worked with include Genentech, Teva Neurosciences, Gilead, AstraZeneca, and Progenity, as well as the National Institutes of Health. Her primary areas of focus have been Stroke, Parkinson's Disease, Multiple Sclerosis, Alzheimer's Disease, Multiple System Atrophy, Macular Degeneration, Cystic Fibrosis, Preeclampsia, Hypertension, *in vitro* diagnostics, Diabetes, Infectious Diseases, Arthritis, hematologic malignancies, and stem cell transplant.

- **Howard Birndorf, MS ScD – Business Development**

Dr. Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego. California. Along with former University of California professor and current venture capitalist Tom Roylston, Birndorf founded San Diego's first biotech in 1978, the monoclonal antibody company, Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Birndorf went on to found a number of other successful companies including Gen-Probe, IDEC, IDE, and Biogen-Idec, and Ligand Pharmaceuticals. Birndorf was also involved in the formation of Genentech (Genentech) and was a founding Director of Neurocrine Biosciences. He was the founder and co-chair of the Coalition for 21st Century Medicine and was founder, Chairman and CEO of Nanogen, Inc. Birndorf received his B.A. in Biology from Oakland University, an M.S. in Biochemistry from Wayne State University, and has received honorary Doctor of Science degrees from Oakland University and Wayne State University.

- **Philip E. Silkoff, MB – Medical Monitor and Consulting Pulmonologist**

Philip E. Silkoff is an adult pulmonary physician who transitioned from academia to industry in 2004. His academic research focused on the measurement of exhaled nitric oxide (NO) as it pertains to respiratory medicine. Exhaled NO is a marker of airway inflammation, and Phil developed patented techniques for NO measurement in man, chaired several societal workshops and published extensively in the field of biomarkers in asthma and COPD. His pharmaceutical career has focused on late phase projects in asthma and COPD, culminating in a successful sNDA filing in 2008 for a COPD therapeutic at AstraZeneca. He subsequently worked in early pulmonary drug development in asthma, COPD, ILD, and sarcoidosis at Janssen. In 2016, he became chief medical officer at Third Pole Therapeutics in Boston which is developing inhaled NO for the treatment of pulmonary hypertension. Phil was involved in a clinical trial run by VCR in 2016 and in 2020 joined VCR as a pulmonary consultant for VCR's projects.

- **Dennis L. Broyles, BA, MSHS, RAC, CCR, CCRP** – Project Manager

